• In late April 2026, A. O. Smith reported first-quarter 2026 results showing lower sales and earnings year over year, cut its full-year 2026 earnings and sales guidance due to ongoing weakness in China, and confirmed that it has repurchased 59.41 million shares for about US$3.06 billion since launching its buyback in 2007.
• At the same time, sentiment weakened as analysts reduced earnings estimates, A. O. Smith was added to the Zacks Rank #5 (Strong Sell) list, and a large institutional holder, FMR LLC, disclosed a more than 7% stake, underscoring both concern about near-term demand and continued institutional interest.
• We’ll now examine how A. O. Smith’s lowered 2026 earnings guidance, especially tied to China weakness, reshapes its previously constructive investment narrative.

Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 33 best rare earth metal stocks of the very few that mine this essential strategic resource.

A. O. Smith Investment Narrative Recap

To own A. O. Smith today, you have to believe its core water heating and treatment franchise can offset pressure from a softer China and a mature North American replacement market. The most important near term catalyst is whether high efficiency and connected products can support earnings within the lowered 2026 guidance range, while the biggest risk remains prolonged weakness and policy uncertainty in China. The latest guidance cut directly reinforces that China risk is very real, not just theoretical.

The most relevant update is the lowered 2026 outlook to diluted EPS of US$3.60 to US$3.90 and net sales of US$3.9 billion to US$4.0 billion. This reset explicitly ties expectations to “continued challenging conditions in China,” which may influence how investors weigh long term growth drivers in India and higher margin North American channels against the possibility that China stays a drag longer than currently assumed.

Yet beneath the long term story, investors should be aware that prolonged China weakness could...

A. O. Smith's narrative projects $4.3 billion revenue and $595.4 million earnings by 2029. This requires 4.0% yearly revenue growth and about a $67.8 million earnings increase from $527.6 million today.

Uncover how A. O. Smith's forecasts yield a $71.30 fair value, a 18% upside to its current price.

Exploring Other Perspectives

Before this reset, the most optimistic analysts were assuming A. O. Smith could reach about US$4.4 billion of revenue and roughly US$660 million of earnings, which is a much more upbeat view than the cautious tone implied by the latest China driven guidance cut. As you weigh these new results against that prior optimism about margin expansion and high efficiency product adoption, it is worth recognizing how widely views can differ and exploring how your own expectations compare.

Explore 4 other fair value estimates on A. O. Smith - why the stock might be worth just $71.30!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your A. O. Smith research is our analysis highlighting 5 key rewards that could impact your investment decision.
• Our free A. O. Smith research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate A. O. Smith's overall financial health at a glance.

No Opportunity In A. O. Smith?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• We've uncovered the 12 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 16 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• AI is about to change healthcare. These 35 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.